Merck & Co. plans to invest $1 billion in a Delaware manufacturing plant, enhancing domestic production and creating 4,000 jobs. This facility will produce Keytruda, bolstering Merck's supply chain amid tariff pressures, marking a key move in U.S. pharma manufacturing.